Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00023738
Other study ID # CDR0000068855
Secondary ID RTOG-S-0121
Status Completed
Phase Phase 1/Phase 2
First received September 13, 2001
Last updated June 20, 2013
Start date August 2001
Est. completion date October 2003

Study information

Verified date December 2010
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy, SU5416, and radiation therapy before and after surgery may kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy, SU5416, radiation therapy, and surgery in treating patients who have soft tissue sarcoma.


Description:

OBJECTIVES:

- Determine the maximum tolerated dose of SU5416 when administered with neoadjuvant chemotherapy and radiotherapy and adjuvant chemotherapy in patients with high-grade stage IIC-III soft tissue sarcoma.

- Determine the disease-free survival, local control, and overall survival in patients treated with this regimen.

- Determine histological response in patients treated with this regimen.

- Determine the toxicity of this regimen in these patients.

- Determine the quantitative antiangiogenic effects of SU5416 in patients treated with this regimen.

OUTLINE: This is a dose-escalation study of SU5416.

Patients receive neoadjuvant chemotherapy comprising doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients also receive filgrastim (G-CSF) subcutaneously once daily beginning on day 5 and continuing until blood counts recover. Patients undergo 2 courses of radiotherapy, given once daily for 11 doses per course over days 7-20 and 28-41. Patients also receive SU5416 IV over 1 hour twice weekly beginning on day 1 and continuing until 2 days before surgery. Patients undergo surgical resection on day 80. Patients then receive adjuvant chemotherapy comprising doxorubicin, ifosfamide, and dacarbazine IV continuously on days 101-103, 122-124, and 143-145. Patients also receive SU5416 IV over 1 hour twice weekly beginning on day 101 and continuing until the end of adjuvant chemotherapy. Patients with positive surgical margins receive additional radiotherapy beginning 2 weeks after resection for a total of 8 doses.

Cohorts of 3-6 patients receive escalating doses of SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 68-80 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date October 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed stage IIC-III primary or locally recurrent soft tissue sarcoma

- Grade 2 or 3 on grade 1-3 scale OR

- Grade 3 or 4 on grade 3-4 scale

- Tumor size at least 8 cm in diameter

- Tumor located on upper extremities (including shoulder), lower extremities (including hip), or on body wall

- No rhabdomyosarcoma, extraosseous Ewing's sarcoma, primitive neuroectodermal tumors, osteosarcoma or chondrosarcoma, Kaposi's sarcoma or angiosarcoma of the scalp or face, or any sarcoma of the head and neck

- No evidence of lung metastases

- Maximum of 4 chest lesion no greater than 3 mm in diameter each on preoperative chest CT scans

- Lesions no greater than 1 cm in diameter allowed if stable for at least 1 year and fit criteria for granulomas

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Zubrod 0-1

Life expectancy:

- At least 2 years

Hematopoietic:

- WBC at least 4,000/mm^3 OR

- Absolute neutrophil count at least 1,800/mm^3

- Platelet count at least 150,000/mm^3

- No prior bleeding or clotting diathesis

Hepatic:

- Bilirubin no greater than 1.5 mg/dL

- AST and ALT no greater than 1.5 times upper limit of normal

- PT and PTT less than 1.25 times normal (not on coumadin)

Renal:

- Creatinine no greater than 1.5 mg/dL OR

- Creatinine clearance greater than 60 mL/min

Cardiovascular:

- LVEF greater than 50%

- History of atherosclerotic coronary artery disease (CAD) requiring bypass surgery allowed provided surgery occurred at least 1 year prior to study entry

- No uncompensated CAD on electrocardiogram or physical examination

- No myocardial infarction or severe or unstable angina within the past 6 months

- No New York Heart Association class II-IV heart disease

- No congestive heart failure

- No severe peripheral vascular disease

- No peripheral vascular disease with diabetes mellitus

- No deep venous or arterial thrombosis (including pulmonary embolism) within the past 3 months

Other:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Fibrin split products less than 2 times normal

- Fibrinogen greater than 200 mg/dL

- No active uncontrolled bacterial, viral, or fungal infection

- No known hypersensitivity to E. coli-derived proteins

- No contraindications to limb-salvage surgery

- No other prior or concurrent malignancy within the past 5 years except surgically treated carcinoma in situ of the cervix or squamous or basal cell skin cancer

- No other serious medical or psychiatric illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No prior biologic therapy

Chemotherapy:

- No prior chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior radiotherapy

Surgery:

- More than 2 weeks since minor surgery

- More than 4 weeks since major surgery

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
filgrastim

Drug:
dacarbazine

doxorubicin hydrochloride

ifosfamide

semaxanib

Procedure:
conventional surgery

Radiation:
radiation therapy


Locations

Country Name City State
Canada Tom Baker Cancer Center - Calgary Calgary Alberta
Canada Cross Cancer Institute Edmonton Alberta
Canada CHUS-Hopital Fleurimont Fleurimont Quebec
Canada Nova Scotia Cancer Centre Halifax Nova Scotia
Canada Cancer Care Ontario-Hamilton Regional Cancer Centre Hamilton Ontario
Canada Kingston Regional Cancer Centre Kingston Ontario
Canada Cancer Care Ontario-London Regional Cancer Centre London Ontario
Canada Centre Hospitalier de l'Universite de Montreal Montreal Quebec
Canada McGill University Montreal Quebec
Canada Ottawa Regional Cancer Centre Ottawa Ontario
Canada Centre Hospitalier Universitaire de Quebec Quebec City Quebec
Canada Allan Blair Cancer Centre Regina Saskatchewan
Canada Saint John Regional Hospital Saint John New Brunswick
Canada Saskatoon Cancer Centre Saskatoon Saskatchewan
Canada Newfoundland Cancer Treatment and Research Foundation St. Johns Newfoundland and Labrador
Canada Northeastern Ontario Regional Cancer Centre, Sudbury Sudbury Ontario
Canada Northwestern Ontario Regional Cancer Centre, Thunder Bay Thunder Bay Ontario
Canada Princess Margaret Hospital Toronto Ontario
Canada Toronto Sunnybrook Regional Cancer Centre Toronto Ontario
United States Akron City Hospital Akron Ohio
United States Akron General Medical Center Akron Ohio
United States Cancer Center of Albany Medical Center Albany New York
United States Radiation Oncology Associates of Albuquerque Albuquerque New Mexico
United States Lehigh Valley Hospital Allentown Pennsylvania
United States Harrington Cancer Center Amarillo Texas
United States St. John's Medical Center Anderson Indiana
United States CCOP - Ann Arbor Regional Ann Arbor Michigan
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States Anne Arundel Oncology Center Annapolis Maryland
United States Northwest Community Hospital Arlington Heights Illinois
United States CCOP - Atlanta Regional Atlanta Georgia
United States Emory University Hospital - Atlanta Atlanta Georgia
United States Greater Baltimore Medical Center and Cancer Center Baltimore Maryland
United States Harbor Hospital Center Baltimore Maryland
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Sinai Hospital of Baltimore Baltimore Maryland
United States Mary Bird Perkins Cancer Center Baton Rouge Louisiana
United States St. Luke's Hospital Regional Cancer Center Bethlehem Pennsylvania
United States CCOP - Montana Cancer Consortium Billings Montana
United States University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama
United States Bloomington Hospital Bloomington Indiana
United States Massachusetts General Hospital Cancer Center Boston Massachusetts
United States New York Methodist Hospital Brooklyn New York
United States State University of New York Health Science Center at Brooklyn Brooklyn New York
United States Roswell Park Cancer Institute Buffalo New York
United States Vermont Cancer Center Burlington Vermont
United States Lineberger Comprehensive Cancer Center, UNC Chapel Hill North Carolina
United States Cancer Center at the University of Virginia Charlottesville Virginia
United States Northwestern Memorial Hospital Chicago Illinois
United States Barrett Cancer Center, The University Hospital Cincinnati Ohio
United States Christ Hospital Cincinnati Ohio
United States Cleveland Clinic Taussig Cancer Center Cleveland Ohio
United States Ireland Cancer Center Cleveland Ohio
United States University Hospitals of Cleveland Cleveland Ohio
United States Finger Lakes Radiation Oncology Center Clifton Springs New York
United States Memorial Hospital Cancer Center Colorado Springs Colorado
United States Ellis Fischel Cancer Center - Columbia Columbia Missouri
United States Arthur G. James Cancer Hospital - Ohio State University Columbus Ohio
United States CCOP - Columbus Columbus Ohio
United States Medical Center/John B. Amos Community Cancer Center Columbus Georgia
United States Mount Diablo Medical Center Concord California
United States Northeast Medical Center Concord North Carolina
United States Geisinger Medical Center Danville Pennsylvania
United States Fitzgerald Mercy Hospital Darby Pennsylvania
United States CCOP - Central Illinois Decatur Illinois
United States University of Colorado Cancer Center Denver Colorado
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Henry Ford Hospital Detroit Michigan
United States Delaware County Memorial Hospital Drexel Hill Pennsylvania
United States Cancer Center and Beckman Research Institute, City of Hope Duarte California
United States Wendt Regional Cancer Center of Finley Hospital Dubuque Iowa
United States Veterans Affairs Medical Center - East Orange East Orange New Jersey
United States Pocono Cancer Center East Stroudsburg Pennsylvania
United States John F. Kennedy Medical Center Edison New Jersey
United States Trinitas Hospital - Jersey Street Campus Elizabeth New Jersey
United States Hurley Medical Center Flint Michigan
United States McLaren Regional Cancer Center Flint Michigan
United States California Cancer Center Fresno California
United States Saint Agnes Cancer Center Fresno California
United States University of Florida Health Science Center Gainesville Florida
United States University of Texas Medical Branch Galveston Texas
United States Saint Mary's Hospital and Medical Center Grand Junction Colorado
United States St. Vincent Hospital Green Bay Wisconsin
United States Sutter Health West Cancer Research Group Greenbrae California
United States CCOP - Greenville Greenville South Carolina
United States East Carolina University School of Medicine Greenville North Carolina
United States RMH Regional Cancer Center Harrisonburg Virginia
United States Ingalls Memorial Hospital Harvey Illinois
United States Milton S. Hershey Medical Center Hershey Pennsylvania
United States MBCCOP - Hawaii Honolulu Hawaii
United States University of Texas - MD Anderson Cancer Center Houston Texas
United States Comprehensive Cancer Institute of Huntsville Huntsville Alabama
United States Huntsville Hospital System Huntsville Alabama
United States Cape Cod Hospital Hyannis Massachusetts
United States Clarian Health Partners Inc. Indianapolis Indiana
United States Community Hospitals of Indianapolis - Regional Cancer Center Indianapolis Indiana
United States Veterans Affairs Medical Center - Indianapolis (Roudebush) Indianapolis Indiana
United States Jackson-Madison County General Hospital Jackson Tennessee
United States Veterans Affairs Medical Center - Boston (Jamaica Plain) Jamaica Plain Massachusetts
United States CCOP - Kalamazoo Kalamazoo Michigan
United States CCOP - Kansas City Kansas City Missouri
United States CCOP - Dayton Kettering Ohio
United States Gundersen Lutheran Medical Foundation La Crosse Wisconsin
United States Wilford Hall - 59th Medical Wing Lackland Air Force Base Texas
United States CCOP - Southern Nevada Cancer Research Foundation Las Vegas Nevada
United States Norris Cotton Cancer Center Lebanon New Hampshire
United States Albert B. Chandler Medical Center, University of Kentucky Lexington Kentucky
United States Central Baptist Hospital Lexington Kentucky
United States Loma Linda University Medical Center Loma Linda California
United States Veterans Affairs Medical Center - Long Beach Long Beach California
United States Monmouth Medical Center Long Branch New Jersey
United States Jonsson Comprehensive Cancer Center, UCLA Los Angeles California
United States USC/Norris Comprehensive Cancer Center and Hospital Los Angeles California
United States James Graham Brown Cancer Center Louisville Kentucky
United States Louisville Radiation Oncology Louisville Kentucky
United States Joe Arrington Cancer Research and Treatment Center Lubbock Texas
United States Southern Wisconsin Radiotherapy Center Madison Wisconsin
United States University of Wisconsin Comprehensive Cancer Center Madison Wisconsin
United States Merle M. Mahr Cancer Center Madisonville Kentucky
United States Elliot Regional Cancer Center Manchester New Hampshire
United States CCOP - North Shore University Hospital Manhasset New York
United States Marquette General Hospital Marquette Michigan
United States Marshfield Clinic Marshfield Wisconsin
United States Loyola University Medical Center Maywood Illinois
United States Health First Holmes Regional Medical Center Melbourne Florida
United States University of Tennessee, Memphis Cancer Center Memphis Tennessee
United States Community Memorial Hospital Menomonee Falls Wisconsin
United States Baptist Hospital of Miami Miami Florida
United States Sylvester Cancer Center, University of Miami Miami Florida
United States Veterans Affairs Medical Center - Miami Miami Florida
United States CCOP - Mount Sinai Medical Center Miami Beach Florida
United States MidMichigan Medical Center - Midland Midland Michigan
United States South Jersey Regional Cancer Center Millville New Jersey
United States Columbia Hospital Milwaukee Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin
United States St. Luke's Medical Center Milwaukee Wisconsin
United States Trinity Cancer Care Center Minot North Dakota
United States MBCCOP - Gulf Coast Mobile Alabama
United States Alabama Oncology, LLC Montgomery Alabama
United States Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County Mount Holly New Jersey
United States Ball Memorial Hospital Muncie Indiana
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee
United States Cancer Institute of New Jersey New Brunswick New Jersey
United States CCOP - Ochsner New Orleans Louisiana
United States MBCCOP - LSU Health Sciences Center New Orleans Louisiana
United States Tulane University School of Medicine New Orleans Louisiana
United States Herbert Irving Comprehensive Cancer Center New York New York
United States Newark Beth Israel Medical Center Newark New Jersey
United States CCOP - Bay Area Tumor Institute Oakland California
United States St. Anthony Hospital Oklahoma City Oklahoma
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Methodist Cancer Center - Omaha Omaha Nebraska
United States Nebraska Health System Omaha Nebraska
United States Florida Radiation Oncology Group Orange Park Florida
United States MD Anderson Cancer Center Orlando Orlando Florida
United States Bay Medical Center Panama City Florida
United States Gulf Coast Cancer Treatment Center Panama City Florida
United States Lutheran General Cancer Care Center Park Ridge Illinois
United States Huntington Cancer Center Pasadena California
United States Methodist Medical Center of Illinois Peoria Illinois
United States Albert Einstein Cancer Center Philadelphia Pennsylvania
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Kimmel Cancer Center of Thomas Jefferson University - Philadelphia Philadelphia Pennsylvania
United States University of Pennsylvania Cancer Center Philadelphia Pennsylvania
United States Veterans Affairs Medical Center - Philadelphia Philadelphia Pennsylvania
United States Foundation for Cancer Research and Education Phoenix Arizona
United States Mercy Hospital of Pittsburgh Pittsburgh Pennsylvania
United States University of Pittsburgh Cancer Institute Pittsburgh Pennsylvania
United States Western Pennsylvania Hospital Pittsburgh Pennsylvania
United States Champlain Valley Physicians Hospital Medical Center Plattsburgh New York
United States Atlantic City Medical Center Pomona New Jersey
United States Cancer Care Center Pomona California
United States CCOP - Columbia River Program Portland Oregon
United States Maine Medical Center Portland Maine
United States Naval Medical Center, Portsmouth Portsmouth Virginia
United States Vassar Brothers Hospital Poughkeepsie New York
United States Roger Williams Medical Center/BUSM Providence Rhode Island
United States Southeastern Wisconsin Regional Cancer Center Racine Wisconsin
United States Reading Hospital and Medical Center Reading Pennsylvania
United States Bon-Secours - St. Mary's Hospital Richmond Virginia
United States Massey Cancer Center Richmond Virginia
United States Valley Hospital Ridgewood New Jersey
United States Mayo Clinic Cancer Center Rochester Minnesota
United States University of Rochester Cancer Center Rochester New York
United States Regional Radiation Oncology Center at Rome Rome Georgia
United States William Beaumont Hospital Royal Oak Michigan
United States Radiation Oncology Center - Sacramento Sacramento California
United States Dixie Regional Medical Center Saint George Utah
United States Mallinckrodt Institute of Radiology Saint Louis Missouri
United States St. Louis University Health Sciences Center Saint Louis Missouri
United States CCOP - Metro-Minnesota Saint Louis Park Minnesota
United States Peninsula Regional Medical Center Salisbury Maryland
United States Latter Day Saints Hospital Salt Lake City Utah
United States University of Utah Health Sciences Center Salt Lake City Utah
United States Radiation Medical Group, Inc. San Diego California
United States UCSF Cancer Center and Cancer Research Institute San Francisco California
United States O'Connor Hospital San Jose California
United States CCOP - Santa Rosa Memorial Hospital Santa Rosa California
United States Sarasota Radiation and Medical Oncology Center Sarasota Florida
United States Mercy Hospital Cancer Center - Scranton Scranton Pennsylvania
United States Virginia Mason Medical Center Seattle Washington
United States CCOP - Northern Indiana CR Consortium South Bend Indiana
United States CCOP - Upstate Carolina Spartanburg South Carolina
United States Deaconess Medical Center Spokane Washington
United States Cancer Research for the Ozarks Springfield Missouri
United States CCOP - Cancer Research for the Ozarks Springfield Missouri
United States CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. Syracuse New York
United States Tallahassee Memorial Healthcare Tallahassee Florida
United States H. Lee Moffitt Cancer Center and Research Institute Tampa Florida
United States CCOP - Toledo Community Hospital Oncology Program Toledo Ohio
United States Community Medical Center Toms River New Jersey
United States David Grant Medical Center Travis Air Force Base California
United States St. Francis Medical Center Trenton New Jersey
United States William Beaumont Hospital - Troy Troy Michigan
United States St. John Health System Tulsa Oklahoma
United States Radiation Oncology Associates of West Alabama Tuscallosa Alabama
United States Associated Radiologists, P.A. Warren New Jersey
United States Waukesha Memorial Hospital Waukesha Wisconsin
United States Schiffler Cancer Center Wheeling West Virginia
United States Wilkes Barre General Hospital Wilkes-Barre Pennsylvania
United States CCOP - Christiana Care Health Services Wilmington Delaware
United States CCOP - Southeast Cancer Control Consortium Winston-Salem North Carolina
United States Comprehensive Cancer Center at Wake Forest University Winston-Salem North Carolina
United States Yakima Valley Memorial Hospital Yakima Washington
United States Riverhill Radiation Oncology Yonkers New York
United States York Hospital York Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Radiation Therapy Oncology Group National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

See also
  Status Clinical Trial Phase
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT04535713 - GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Phase 2
Completed NCT03521531 - Burden and Medical Care of Sarcoma in Germany
Completed NCT02496520 - Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults Phase 1/Phase 2
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT04052334 - Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Phase 1
Completed NCT01593748 - A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Completed NCT01879085 - Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Phase 1/Phase 2
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2